Lenacapavir's trial programme covers two very different situations: people with virus resistant to everything else, and people with no infection at all. The results in both have been notable.
What did CAPELLA test?
Lenacapavir added to an optimised background regimen in people with multidrug-resistant HIV whose treatment was failing. This is a group with very limited options, where success is measured against a low baseline.
What did it find?
A substantial proportion achieved viral suppression that had not been achievable on their existing regimens, with increases in CD4 count. It established the drug in a group who genuinely needed a new class, and it was the basis for its initial licensing.
What was PURPOSE 1?
A prevention trial in adolescent girls and young women in South Africa and Uganda, comparing twice-yearly lenacapavir against daily oral PrEP. It reported no infections among participants receiving lenacapavir, which is an extraordinary result in a population and setting where HIV incidence is high.
What was PURPOSE 2?
The parallel trial in men who have sex with men and in transgender and gender-diverse people, across several countries. It also reported very high efficacy, with almost no infections in the lenacapavir group and a large reduction compared with background incidence.
Why were these results so striking?
Because the effectiveness was close to complete in populations where oral PrEP has historically been undermined by adherence. Two injections a year removes almost every practical obstacle to taking prevention consistently, which is what the numbers reflect.
Did resistance emerge?
A very small number of infections occurred across the programme, and capsid resistance mutations were identified in some. As with any long-acting agent, the concern concentrates on infections acquired while levels are declining after a missed or final dose.
Why does resistance matter more here?
Because there is currently no second capsid inhibitor. Resistance to lenacapavir closes off a class that has only one member, which is a different proposition from resistance to a drug with several alternatives in its class. This is the strongest argument for testing before every injection.
What about tolerability?
Injection site reactions were the dominant finding: nodules under the skin at the injection site, sometimes persisting for weeks or months, along with pain and swelling. Discontinuation because of them was uncommon, and most participants continued.
What is known about the tail?
Lenacapavir remains detectable for a long period after the last injection, declining gradually over many months. That pharmacokinetic profile is what allows six-monthly dosing and is also the source of the resistance risk after stopping.
What questions remain?
How the tail is best managed when someone disengages from care. How the six-monthly service model works at scale. How access and cost will be handled internationally, which has been the subject of considerable public debate. And long-term safety, since experience is still relatively short.
What is the overall picture?
Exceptional efficacy in trials, a genuinely novel mechanism, and a set of practical and access questions that are not about whether the drug works.
How much real-world data exists?
Considerably less than for older drugs, since it reached use in the early 2020s. The trial results are strong and the long-term picture, including how the twice-yearly model works outside study conditions, is still being established.
What is being studied now?
Combinations of lenacapavir with other long-acting agents, which could produce fully injectable treatment regimens given twice yearly. That work is ongoing rather than available, and it is the direction the field is moving.
Where can you read the evidence yourself?
NAM aidsmap summarises HIV research reliably and without overstatement, and the British HIV Association publishes the guidelines UK clinicians actually follow. Both are freely available and are considerably more useful than a general search, which tends to surface material from other countries with different practice.
Does the evidence apply to you?
Trials recruit particular populations, and their results transfer best to people who resemble the participants. Where a study excluded a group, that is a gap rather than a negative finding. It is a fair question to ask a clinician which evidence their recommendation for you actually rests on.